X4 Pharmaceuticals Inc

Research X4 Pharmaceuticals Inc (XFOR) on Bullrun: market cap USD 398.97M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerXFOR
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 398.97M
• Financial periodFY2025
• RevenueUSD 35.11M
• Revenue growth1273.2%
• Net income-USD 79.20M
• Free cash flow-USD 85.62M
• Gross margin83.6%

Valuation Snapshot

latest market cap is USD 398.97M.

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd.

Frequently asked questions

What is X4 Pharmaceuticals Inc's market cap?

X4 Pharmaceuticals Inc's market capitalization is USD 398.97M.

What does X4 Pharmaceuticals Inc do?

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.